Risk factors
Lantern Pharma (LTRN) risk factors
Item 1A of every Lantern Pharma Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks2 new1 dropped3 reworded
Lantern Pharma faces a going concern doubt requiring urgent funding for R&D and clinical trials.
Filed Mar 30, 2026 - FY2024 10-K risk factors62 risks
Lantern Pharma faces substantial operating losses, totaling $20,781,000 in 2024, and requires significant additional capital. The company relies heavily on its unproven RADR platform and clinical-stage drug candidates like LP-300, LP-184, and LP-284.
Filed Mar 27, 2025